Helixgate https://validator.w3.org/feed/docs/rss2.html Biotech in Switzerland: 10 companies to watch in 2027  Histone lysine demethylases in the third decade: biology and therapeutic prospects Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress FDA’s new rare disease framework aims to leverage patient voices for better innovation Novo’s troubled cardio drug could find niche in less sick patients Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign Vir’s hepatitis delta combo tamps down virus as Gilead showdown looms Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3 Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease Update: Compass submits psilocybin depression drug for approval after stock wobbles Update: FDA investigates Novartis’ Zolgensma following 9 cases of tumors in treated patients Shortly after Vertex acquisition, Crinetics will cut 78 employees Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys Science & Research | Generic Drugs FDA Database Study Differentiates Cutaneous Adverse Events for Liver Cancer Therapies Next-Generation Antimalarial Research Explores Innovative Biological Targets and Modern Discovery Strategies FDA Expedited Investigational New Drug (IND) Pilot Program 2026 Meeting Materials | Pediatric Advisory Committee PDUFA and BsUFA Quarterly Hiring Updates STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer FDA approves durvalumab for limited-stage small cell lung cancer FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma FDA approves axatilimab-csfr for chronic graft-versus-host disease FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report Post-election pricing outlook: stormy with a chance of compromise Home